Photo of Blake Byers

Blake Byers

General Partner

Biotechnology is undergoing a platform shift with the advent of cell and gene therapy. These new drugs are not the single agents of the past; rather, they are logically controlled products, both with embedded and rationally designed logical processes. The versioning enabled by these drug platforms is going to reshape how biotech drug development works, and offers the first opportunity since the 1980s to build new standalone drug development companies that can iteratively improve human health.